The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies
Authors:
Open Access
- 30 October 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1494802
Abstract
PIK3CA gene encodes the p110α catalytic subunit of PI3K, which regulates the PI3K/AKT/mTOR signaling pathway. PIK3CA gene mutation is one of the most common mutations in colorectal cancer (CRC), affecting about 15%–20% of CRC patients. PIK3CA gene mutation leads to the persistent activation of the PI3K/AKT/mTOR signaling pathway, which promotes the proliferation, invasion, metastasis, and drug resistance of CRC. This article provides a summary of the key detection methods for PIK3CA gene mutation, and provides an introduction to the existing colorectal cancer treatments and their practical applications in the clinic. Besides, this article summarizes the role and mechanism of PIK3CA gene mutation in the occurrence and development of CRC. It also explores the relationship between PIK3CA gene mutation and the clinical features and prognosis of CRC. This article focuses on the influence and mechanism of PIK3CA gene mutation on the targeted therapy and immunotherapy of CRC, and discusses the potential value and future direction of PIK3CA gene mutation in the personalized therapy of CRC. We aim to provide new perspectives and ideas for the precise diagnosis and treatment of CRC.Keywords
Funding Information
- Southwest Medical University (KY2023060)
This publication has 165 references indexed in Scilit:
- Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal CancerJAMA Oncology, 2023
- Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal CancerJAMA, 2023
- NICD3 regulates the expression of MUC5AC and MUC2 by recruiting SMARCA4 and is involved in the differentiation of mucinous colorectal adenocarcinomaMolecular Oncology, 2022
- Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal CancerJAMA Oncology, 2021
- Diagnosis and Treatment of Metastatic Colorectal CancerJAMA, 2021
- Gene mutation profiling in Chinese colorectal cancer patients and its association with clinicopathological characteristics and prognosisCancer Medicine, 2019
- Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancerCancer, 2019
- PIK3CA‐related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluationAmerican Journal of Medical Genetics Part A, 2014
- Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cellsInternational Journal of Cancer, 2013
- Oncogenic PIK3CA mutations in colorectal cancers and polypsInternational Journal of Cancer, 2011